Risks
4 risks
Risk Intelligence
Red Sea freight disruption impact
View Risks →Ajanta Pharma Limited — Q4 FY24
Ajanta Pharma delivered a strong Q4 FY24 with revenue of INR 1,054 crore (+20% YoY), EBITDA of INR 278 crore (+86% YoY), and PAT of INR 203 crore (+66% YoY).
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma delivered a strong Q4 FY24 with revenue of INR 1,054 crore (+20% YoY), EBITDA of INR 278 crore (+86% YoY), and PAT of INR 203 crore (+66% YoY). Growth was driven by branded generics (India +14%, Asia +18%, Africa +13%) and a US generic rebound (+32% YoY) aided by lower price erosion and API cost tailwinds. EBITDA margin expanded to 26% (Q4) and 28% for the full year. Management guided for low-teens overall revenue growth in FY25, with branded generics in mid-teens and US generics in mid-single digits. EBITDA margin is expected to sustain at ~28%, with potential 100 bps upside if freight costs normalize. Key risks include Red Sea freight disruptions (~INR 30 cr impact) and unpredictable institutional business.
अजंता फार्मा ने चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई ₹1,054 करोड़ रही, जो पिछले साल से 20% ज्यादा है। मुनाफा ₹203 करोड़ रहा, जो 66% बढ़ा है। यह वृद्धि भारत, एशिया और अफ्रीका में दवाओं की बिक्री बढ़ने और अमेरिका में जेनेरिक दवाओं की मांग सुधरने से हुई। कंपनी का मार्जिन (मुनाफा दर) 26% रहा। अगले साल कमाई 10-14% बढ़ने का अनुमान है। मार्जिन 28% के आसपास रहने की उम्मीद है, लेकिन शिपिंग लागत कम हुई तो 1% और बढ़ सकता है। मुख्य जोखिम लाल सागर के रास्ते में माल ढुलाई में रुकावट (₹30 करोड़ का असर) और अनिश्चित संस्थागत कारोबार है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Business Growth (Q4)
14%
+14% YoY
India branded generics grew 14% YoY in Q4, outpacing IPM growth of ~8-9%.
US Generic Sales Growth (Q4)
32%
+32% YoY
US generics posted 32% YoY growth in Q4, driven by lower price erosion and product shortages.
EBITDA Margin (FY24)
28%
+700 bps YoY
Full-year EBITDA margin expanded to 28% from 21% in FY23, aided by lower API and logistics costs.
Total MR Count
~5,000
+200 YoY
Total medical representatives stood at ~5,000, with ~200 added in India and plans to add 200 more in international markets.
What Changed vs Last Quarter
NEW
Overall revenue growth of low teens in FY25
Management expects consolidated revenue to grow in low teens, with branded generics growing mid-teens and US generics in mid-single digits.
NEW
India business to grow 10-11% in FY25
India branded generics are expected to grow 200-300 bps faster than IPM (forecast ~8%), implying 10-11% growth.
NEW
EBITDA margin to sustain at ~28% in FY25
Management guided for EBITDA margin of ~28% for FY25, with potential 100 bps improvement if freight costs normalize.
NEW
CapEx of INR 175-200 crore in FY25
Capital expenditure for FY25 is estimated at INR 175-200 crore, including maintenance capex.
DROPPED
FY24 EBITDA margin guidance revised to 27% ±1%
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
DROPPED
India business to grow low double digits in FY24
India business expected to grow 12-13% for full year FY24, with Q4 aspiration to cross 15%.
DROPPED
Asia branded to grow low teens in FY24
Asia branded business expected to grow low double digits for full year FY24.
DROPPED
Africa branded to grow mid to high single digits in FY24
Africa branded business expected to grow mid to high single digits for full year FY24.
NEW RISK
Red Sea freight disruption impact
Increased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.
NEW RISK
US price erosion may be higher than guided
An analyst questioned whether high single-digit price erosion is aggressive; management acknowledged it's their estimate but could be worse.
NEW RISK
M&A valuations remain high for premium assets
Management noted that while valuations have tapered, premium specialty portfolios are still expensive, limiting inorganic growth options.
RISK GONE
Red Sea crisis impacting freight costs and transit times
Freight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.
RISK GONE
US price erosion remains an unknown variable
While current price erosion is stable at high single digits, any acceleration could impact US generics profitability and overall margins.
RISK GONE
NLEM price revisions impacting India cardiology growth
Cardiology growth was lower than IPM due to price revision in a major product in December 2022, and competitive intensity has increased.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
Mentioned in Q2 FY24, Q3 FY24
Asia branded business expected to grow low double digits for full year FY24.
Mentioned in Q1 FY24, Q2 FY24
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
Fast read
Guidance and risk preview
Management expects consolidated revenue to grow in low teens, with branded generics growing mid-teens and US generics in mid-single digits.
Increased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.
View Risks →